- CFO Spotlights
- Profiles
- John Tattory
Profile
John Tattory
Interim Chief Financial Officer, principal financial officer and principal accounting officer, TransCode Therapeutics, Inc.
In the seat, on an interim basis. First published here October 28, 2026; built from records as of October 28, 2026.
John Tattory has been Interim Chief Financial Officer, principal financial officer and principal accounting officer of TransCode Therapeutics, Inc. since September 9, 2026, according to the company's filing of September 11, 2026.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| TransCode Therapeutics, Inc. (RNAZ) Pharmaceutical Preparations | Interim Chief Financial Officer, principal financial officer and principal accounting officer | In the seat, on an interim basis |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- September 9, 2026effective
TransCode Therapeutics, Inc. named John Tattory Interim Chief Financial Officer, principal financial officer and principal accounting officer, effective September 9, 2026. Profile of Thomas A. Fitzgerald, M.B.A..
John Tattory was appointed to serve as the Company’s Interim Chief Financial Officer, principal financial officer and principal accounting officer, effective as of September 9, 2026.
[1] Filing by TransCode Therapeutics, Inc., filed with the SEC on September 11, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, TransCode Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 11, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or John Tattory wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.